Skip to main content

Table 1 Anthropometric and clinical parameters (expressed as number and percentage or as median and interquartile range) of patients belonging to the study groups: HIV seronegative controls (n = 35) and HIV seropositive patients of Group 1 (treated with 3TC, TDF, EFV, n = 44) and Group 2 (treated with 3TC + AZT; 3TC + TDF + LPV/r, n = 42) with suppressed viremia

From: Linear and non-linear analysis of heart rate variability in HIV-positive patients on two different antiretroviral therapy regimens

  HIV seronegative controls HIV seropositive p value
Group 1 (3TC, TDF, EFV) Group 2 (3TC + AZT; 3TC + TDF + LPV/r)
Number 35 44 42  
Males [n (%)] 21 (60.00) 28 (63.63) 23 (54.76) NS (0.071)
Females [n (%)] 14 (40.00) 16 (36.37) 19 (45.24) NS (0.071)
Age (years)a 34.00 (22.00) 40.50 (15.50) 42.00 (14.25) NS (0.784)
Body mass index (Kg/m2) 24.09 (2.33) 22.20 (6.88) 23.02 (6.11) NS (0.466)
Heart rate (bpm) 71.94 (14.41) 76.00 (13.00) 72.00 (12.75) NS (0.751)
Systolic BP (mmHg) 120 (12) 120 (10) 117.50 (10) NS (0.238)
Diastolic BP [median (mmHg)] 80 (14) 80 (10) 80 (10) NS (0.170)
Duration of HIV infection (yr) - 10.50 (8.00) 14.00 (9.25) NS (0.163)
Duration of ART use (median) (yr) - 10.00 (8.00) 12.50 (9.75) NS (0.969)
CD4 T cell (cells/mm3) - 740.0 (540.5) 521.0 (437.0) 0.039
Tabagism [n (%)] 2 (5.71) 20 (45.45) 9 (21.43) NS (0.486)
Etilism [n (%)] 5 (14.29) 15 (34.09) 12 (28.57) NS (0.298)
Symptoms [n (%)] 0 (0) 10 (22.72) 8 (19.05) NS (0.877)
  1. Note: Data are shown as number itself or as number and percentage or as median (interquartile range). p = significance level from Kruskall-Wallis ANOVA on Ranks, except for CD4 T cell count, in which the Mann–Whitney test was used and the viral load in which the χ2 test was used; NS = nonsignificant; bpm = beats per minute; BP = blood pressure; SD: standard deviation. 3TC = lamivudine, TDF = tenofovir, EFV: efavirenz, AZT = zidovudine, LPV = lopinavir, r = ritonavir
  2. aMedian (SD)